Title： Meta-Analysis of Traditional Chinese Patent Medicine for Ischemic Stroke.
Author： Wu B, Liu M, Liu H, Li W, Tan S, Zhang S, Fang Y.
Resource: Stroke. 2007 Apr 26; [Epub ahead of print]
Abstract： BACKGROUND AND PURPOSE: A large number of traditional Chinese patent medicine (TCPM) are widely used for ischemic stroke in China. The aim of this study was to systematically review the existing clinical evidence on TCPM for ischemic
stroke. METHODS: We identified all TCPM that were listed in the Chinese National
Essential Drug list of 2004 and those commonly used TCPM in current clinical
practice for ischemic stroke. Fifty-nine TCPM were identified for further
evaluation. We applied Cochrane systematic review methods. We searched for
reports of randomized controlled trials and controlled clinical trials on any of
the 59 TCPM for ischemic stroke comparing one TCPM with control. Primary
outcomes included death or dependency at the end of follow-up (at least 3
months) and adverse events. Effects on neurological impairments were a secondary
outcome. RESULTS: One-hundred ninety-one trials (19 338 patients) on 22 TCPM
were available and included, of which 120 were definite or possible randomized
controlled trials and 71 were controlled clinical trials. The methodological
quality of included trials was generally "poor." Few trials reported methods of
randomization. Three trials were randomized, double blind, and
placebo-controlled. Primary outcomes: one trial on Puerarin and one trial on
Shenmai injection assessed death or dependency at the end of long-term follow-up
(at least 3 months) and found no statistically significant difference between 2
groups. The reported adverse events including allergic reaction, headache,
nausea, diarrhea, bellyache, blood pressure change, and subcutaneous ecchymosis.
Most of the adverse events were not severe. Secondary outcomes: analysis of the
secondary outcome, "marked improvement in neurological deficit," showed apparent
benefits of about the same magnitude for all the TCPM studied. Of the 22 TCPM, 8
drugs (Milk vetch, Mailuoning, Ginkgo biloba, Ligustrazine, Danshen agents,
Xuesetong, Puerarin, and Acanthopanax) had relatively more studies and patient
numbers. CONCLUSIONS: There was insufficient good quality evidence on the
effects of TCPM in ischemic stroke on the primary outcome (death or dependency).
We considered the apparent benefit on neurological impairment was as likely to
be attributable to bias from poor methodology as to a real treatment effect.
However, because the agents assessed appeared potentially beneficial and
nontoxic, further randomized controlled trials are justified. Eight drugs could
be further research priorities.
PMID: 17463317
本人认领此文. 如在48小时内未提交译文, 其他战友自由认领.
Title： Meta-Analysis of Traditional Chinese Patent Medicine for Ischemic Stroke.
中成药对缺血性卒中的荟萃分析
Author： Wu B, Liu M, Liu H, Li W, Tan S, Zhang S, Fang Y.
作者：
Resource: Stroke. 2007 Apr 26; [Epub ahead of print]
来源：《中风》。2007，4月26日
Abstract： BACKGROUND AND PURPOSE: A large number of traditional Chinese patent medicine (TCPM) are widely used for ischemic stroke in China. The aim of this study was to systematically review the existing clinical evidence on TCPM for ischemic
stroke.
摘要：背景和目的：在中国，许多中成药广泛用于治疗缺血性卒中。该研究的目的是为了系统地考察中成药用来治疗缺血性卒中的根据。
METHODS: We identified all TCPM that were listed in the Chinese National
Essential Drug list of 2004 and those commonly used TCPM in current clinical
practice for ischemic stroke.
方法：我们鉴定了2004年中国基本用药中的和当前常用于临床缺血性发作的中成药。
Fifty-nine TCPM were identified for further evaluation.
进一步评价了其中56种中成药。
We applied Cochrane systematic review methods.
我们采用了Cochrane系统评价方法
We searched for reports of randomized controlled trials and controlled clinical trials on any of
the 59 TCPM for ischemic stroke comparing one TCPM with control.
我们搜集了有关该59种中成药用于治疗缺血性发作的随机对照试验和临床对照试验与一种中成药的治疗缺血性发作的报告。
Primary outcomes included death or dependency at the end of follow-up (at least 3
months) and adverse events. Effects on neurological impairments were a secondary
outcome.
最初的结果包括死亡或追踪现察至少三个月的药物依赖性和不良反应事件。次级结果包括对神经损伤的影响。
RESULTS: One-hundred ninety-one trials (19 338 patients) on 22 TCPM
were available and included, of which 120 were definite or possible randomized
controlled trials and 71 were controlled clinical trials.
结果：22种可用和内含的中成药用在191次试验中的19338个病人。其中包括120次的明确或可能随机对照试验和71次临床对照试验。
The methodological quality of included trials was generally "poor." Few trials reported methods of randomization. Three trials were randomized, double blind, and
placebo-controlled.
很少有实验报道随机取样的方法。内含的试验方法的质量一般很弱。三种试验分别为随机取样、双盲法、安慰剂给样试验。
Primary outcomes: one trial on Puerarin and one trial on
Shenmai injection assessed death or dependency at the end of long-term follow-up
(at least 3 months) and found no statistically significant difference between 2
groups.
最初结果：评价了服用葛根(黄)素和生脉饮注射液的死亡率或至少三个月的跟踪药物长期依赖性，发现这两组试验并无在统计差异。
The reported adverse events including allergic reaction, headache,
nausea, diarrhea, bellyache, blood pressure change, and subcutaneous ecchymosis.
报道的不良反应包括变态反应，头痛，恶心，腹泻，腹痛，血压变化，皮下淤斑。
Most of the adverse events were not severe.
大多不良反应并不严重。
Secondary outcomes: analysis of the
secondary outcome, "marked improvement in neurological deficit," showed apparent
benefits of about the same magnitude for all the TCPM studied. Of the 22 TCPM, 8
drugs (Milk vetch, Mailuoning, Ginkgo biloba, Ligustrazine, Danshen agents,
Xuesetong, Puerarin, and Acanthopanax) had relatively more studies and patient
numbers.
次级结果：通过次级结果的分析，发现在神经损伤有明显的改良。显示了中成药的研究在神经损伤方面有着同样的重要性。如22种中成药的8种药物（紫云英，银杏，川芎，丹参，血塞通，葛根(黄)素，刺五加）已经有了相对多的研究和病人群体
CONCLUSIONS: There was insufficient good quality evidence on the
effects of TCPM in ischemic stroke on the primary outcome (death or dependency).
结论：在最初的结果（死亡率或依赖性），并没有充分的证据证实用于治疗缺血性发作的中成药的效果 We considered the apparent benefit on neurological impairment was as likely to
be attributable to bias from poor methodology as to a real treatment effect.
我们考虑到中成药在神经损伤的好处同样可能导致我们从弱的方法论到真正的治疗效果偏转过来
However, because the agents assessed appeared potentially beneficial and
nontoxic, further randomized controlled trials are justified. Eight drugs could
be further research priorities.
然而，因为这些药物主要考察其潜在益处和非毒性，进一步随机对照试验将会证实这些。8种药物拥有研究的优先权。
中成药对缺血性卒中的荟萃分析
来源：《中风》。2007，4月26日
摘要：背景和目的：在中国，许多中成药广泛用于治疗缺血性卒中。该研究的目的是为了系统地考察中成药用来治疗缺血性卒中的根据。
方法：我们鉴定了2004年中国基本用药中的和当前常用于临床缺血性发作的中成药。
进一步评价了其中56种中成药。我们采用了Cochrane系统评价方法我们搜集了有关该59种中成药用于治疗缺血性发作的随机对照试验和临床对照试验与一种中成药的治疗缺血性发作的报告。
最初的结果包括死亡或追踪现察至少三个月的药物依赖性和不良反应事件。次级结果包括对神经损伤的影响。
结果：22种可用和内含的中成药用在191次试验中的19338个病人。其中包括120次的明确或可能随机对照试验和71次临床对照试验。很少有实验报道随机取样的方法。内含的试验方法的质量一般很弱。三种试验分别为随机取样、双盲法、安慰剂给样试验。
最初结果：评价了服用葛根(黄)素和生脉饮注射液的死亡率或至少三个月的跟踪药物长期依赖性，发现这两组试验并无在统计差异。报道的不良反应包括变态反应，头痛，恶心，腹泻，腹痛，血压变化，皮下淤斑。大多不良反应并不严重。
次级结果：通过次级结果的分析，发现在神经损伤有明显的改良。显示了中成药的研究在神经损伤方面有着同样的重要性。如22种中成药的8种药物（紫云英，银杏，川芎，丹参，血塞通，葛根(黄)素，刺五加）已经有了相对多的研究和病人群体
结论：在最初的结果（死亡率或依赖性），并没有充分的证据证实用于治疗缺血性发作的中成药的效果。我们考虑到中成药在神经损伤的好处同样可能导致我们从弱的方法论到真正的治疗效果偏转过来。
请按文摘编译格式进行编译
Abstract： BACKGROUND AND PURPOSE: A large number of traditional Chinese patent medicine (TCPM) are widely used for ischemic stroke in China. The aim of this study was to systematically review the existing clinical evidence on TCPM for ischemic
stroke.
摘要：背景和目的：在中国，许多中成药广泛用于治疗缺血性卒中。该研究的目的是为了系统地考察中成药用来治疗缺血性卒中的根据。
METHODS: We identified all TCPM that were listed in the Chinese National
Essential Drug list of 2004 and those commonly used TCPM in current clinical
practice for ischemic stroke. Fifty-nine TCPM were identified for further evaluation.
方法：我们鉴定了2004年中国基本用药中的和当前常用于临床缺血性发作的中成药。
进一步评价了其中56种中成药。我们采用了Cochrane系统评价方法我们搜集了有关该59种中成药用于治疗缺血性发作的随机对照试验和临床对照试验与一种中成药的治疗缺血性发作的报告。
We searched for reports of randomized controlled trials and controlled clinical trials on any of
the 59 TCPM for ischemic stroke comparing one TCPM with control.
我们搜集了有关该59种中成药用于治疗缺血性发作的随机对照试验和临床对照试验与一种中成药的治疗缺血性发作的报告。
Primary outcomes included death or dependency at the end of follow-up (at least 3
months) and adverse events. Effects on neurological impairments were a secondary
outcome.
最初的结果包括死亡或追踪现察至少三个月的药物依赖性和不良反应事件。次级结果包括对神经损伤的影响。
RESULTS: One-hundred ninety-one trials (19 338 patients) on 22 TCPM
were available and included, of which 120 were definite or possible randomized
controlled trials and 71 were controlled clinical trials.
结果：22种可用和内含的中成药用在191次试验中的19338个病人。其中包括120次的明确或可能随机对照试验和71次临床对照试验。
The methodological quality of included trials was generally "poor." Few trials reported methods of randomization. Three trials were randomized, double blind, and placebo-controlled.
很少有实验报道随机取样的方法。内含的试验方法的质量一般很弱。三种试验分别为随机取样、双盲法、安慰剂给样试验。
Primary outcomes: one trial on Puerarin and one trial on Shenmai injection assessed death or dependency at the end of long-term follow-up
(at least 3 months) and found no statistically significant difference between 2 groups.
最初结果：评价了服用葛根(黄)素和生脉饮注射液的死亡率或至少三个月的跟踪药物长期依赖性，发现这两组试验并无在统计差异。
The reported adverse events including allergic reaction, headache,
nausea, diarrhea, bellyache, blood pressure change, and subcutaneous ecchymosis. Most of the adverse events were not severe.
报道的不良反应包括变态反应，头痛，恶心，腹泻，腹痛，血压变化，皮下淤斑。大多不良反应并不严重。
Secondary outcomes: analysis of thesecondary outcome, "marked improvement in neurological deficit," showed apparentbenefits of about the same magnitude for all the TCPM studied. Of the 22 TCPM, 8drugs (Milk vetch, Mailuoning, Ginkgo biloba, Ligustrazine, Danshen agents,
Xuesetong, Puerarin, and Acanthopanax) had relatively more studies and patient numbers.
次级结果：通过次级结果的分析，发现在神经损伤有明显的改良。显示了中成药的研究在神经损伤方面有着同样的重要性。如22种中成药的8种药物（紫云英，银杏，川芎，丹参，血塞通，葛根(黄)素，刺五加）已经有了相对多的研究和病人群体
CONCLUSIONS: There was insufficient good quality evidence on the
effects of TCPM in ischemic stroke on the primary outcome (death or dependency).
结论：在最初的结果（死亡率或依赖性），并没有充分的证据证实用于治疗缺血性发作的中成药的效果
We considered the apparent benefit on neurological impairment was as likely to
be attributable to bias from poor methodology as to a real treatment effect.
我们考虑到中成药在神经损伤的好处同样可能导致我们从弱的方法论到真正的治疗效果偏转过来
However, because the agents assessed appeared potentially beneficial and
nontoxic, further randomized controlled trials are justified. Eight drugs could
be further research priorities.
然而，因为这些药物主要考察其潜在益处和非毒性，进一步随机对照试验将会证实这些。8种药物拥有研究的优先权。
具体格式见置顶贴，或者直接在我的签名档里找。
中药是无可替代的好啊
该研究是四川大学华西医院神经内科吴波博士的最新研究成果
祝贺！
